Certara Completes Acquisition of Chemaxon
Certara, Inc. (NASDAQ: CERT), renowned for its model-informed drug development expertise, has officially acquired Chemaxon, a pioneer in scientific informatics software.
Synergistic Benefits of the Acquisition
Chemaxon develops advanced software utilized by the life sciences sector for in-silico research, while Certara provides innovative modeling and biosimulation tools that predict the pharmacokinetic and pharmacodynamic properties of compounds. The merger of these two companies promises to create unique synergies, offering life sciences companies enhanced solutions that boost productivity and innovation success rates.
Enhancing Scientific Innovation
According to William Feehery, Certara’s CEO, this merger allows the two firms to provide scientists with more precise insights during the drug discovery and development process. This collaboration is expected to significantly improve the efficiency of scientific exploration in pharmaceuticals.
Incorporating Advanced Precision Chemistry
A top priority for the merged organization involves integrating precision chemistry structures along with calculators and predictors into Certara’s D360 scientific informatics applications. This integration aims to optimize prediction accuracy and enhance the drug development process.
Future Developments and Long-Term Goals
In addition to immediate goals, Certara intends to leverage Chemaxon’s robust life sciences capabilities to better utilize GPT technology for drug discovery. Further, they plan to enhance their offerings by bringing in Chemaxon’s products like Design Hub and JChem Engines, which are pivotal in increasing the overall efficiency of drug research.
Commitment to Precision Medicine
Richard Jones, the CEO of Chemaxon, expressed enthusiasm about the combined entity's potential to influence drug discovery positively. He emphasized the importance of accurate scientific predictions as the industry pivots towards precision medicine.
Projected Revenue Growth
Chemaxon is on track to generate software revenue exceeding $20 million, and Certara will revise its 2024 forecasts to reflect this acquisition during its upcoming earnings report.
Documentation and Investor Relations
An insightful document addressing frequently asked questions regarding this transaction is now available on Certara's investor relations page, offering detailed insights for interested stakeholders.
About Certara
Certara is at the forefront of modern drug development, using biosimulation software and technology to usher in transformative changes in traditional methodologies. Currently, it serves more than 2,400 clients spanning biopharmaceutical companies, academic institutions, and regulatory bodies globally.
About Chemaxon
Chemaxon stands out as a foremost cheminformatics firm, dedicated to delivering comprehensive solutions that manage chemical entities. Its services are invaluable for the biotechnology, agrochemicals, and research industries, facilitating efficient decision-making and enhancing the value of chemical information.
Certara Contacts
For further inquiries, please contact Sheila Rocchio at sheila.rocchio@certara.com.
Media Inquiries
Alyssa Horowitz is available for media-related questions at certara@pancomm.com.
Frequently Asked Questions
What is the significance of Certara's acquisition of Chemaxon?
The acquisition enhances Certara's capabilities by integrating Chemaxon's advanced scientific software, improving drug discovery and development processes.
How will this acquisition impact drug discovery?
The merger promises to provide more precise insights for scientists, thereby increasing productivity and success rates in drug development.
What are the future plans for the combined company?
Certara aims to incorporate Chemaxon's technology into its platforms, focusing on precision medicine and enhanced prediction accuracy in drug research.
What is Chemaxon expected to contribute to Certara's revenue?
Chemaxon is projected to generate over $20 million in software revenue, which will be factored into Certara's updated 2024 financial guidance.
Where can more information about this acquisition be found?
Further details and documentation regarding the acquisition are available on Certara's investor relations website.
